CSS
VRCA icon

Cubist Systematic Strategies’s Verrica Pharmaceuticals VRCA Stock Holding History

Cubist Systematic Strategies’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-196
Closed -$1.04K – 3612
2025
Q2 		$1.04K Buy
+196
New +$1.05K ﹤0.01% 2884
2023
Q2 		– Sell
-1,736
Closed -$113K – 4358
2023
Q1 		$113K Buy
+1,736
New +$105K ﹤0.01% 3418
2022
Q4 		– Sell
-942
Closed -$28K – 4620
2022
Q3 		$28K Buy
942
+822
+685% +$28.2K ﹤0.01% 4202
2022
Q2 		$2K Buy
+120
New +$6.03K ﹤0.01% 4320
2019
Q1 		– Sell
-43
Closed -$3K – 2434
2018
Q4 		$3K Sell
43
-148
-77% -$18K ﹤0.01% 2005
2018
Q3 		$31K Buy
+191
New +$32.6K ﹤0.01% 1765

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

Cubist Systematic Strategies's VRCA Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 196 shares — an estimated $1.04K sold.

Cubist Systematic Strategies first reported a position in VRCA in Q3 2018 and held it in 6 quarters. The position peaked at $113K in Q1 2023. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 196 Verrica Pharmaceuticals shares in Q3 2025, an estimated $1.04K.
  • Cubist Systematic Strategies first reported a position in Verrica Pharmaceuticals in Q3 2018 and held it in 6 quarters.
  • Cubist Systematic Strategies's Verrica Pharmaceuticals position peaked at $113K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.